ViroPharma To Participate In Two November Healthcare Investor Conferences

  ViroPharma To Participate In Two November Healthcare Investor Conferences

PR Newswire

EXTON, Pa., Nov. 8, 2012

EXTON, Pa., Nov. 8, 2012 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq:
VPHM) today announced that Vincent Milano, president and chief executive
officer of ViroPharma, will present at the 2012 Jefferies Global Healthcare
Conferenceat 11:20 AM GMT (6:20 AM ET) on Thursday, November 15, 2012. The
conference is being held at the Waldorf Hilton in London.

ViroPharma also announced that Charles Rowland, vice president and chief
financial officer of ViroPharma, will present at the Piper Jaffray 24^th
Annual Healthcare Conference at 2:00 PM ET on Wednesday, November 28, 2012.
The conference is being held at the New York Palace Hotel.

ViroPharma's presentations will be webcast live for investors through and available for a period of 14 days following the

About ViroPharma Incorporated

ViroPharma Incorporated is an international biopharmaceutical company
committed to developing and commercializing novel solutions for physician
specialists to address unmet medical needs of patients living with diseases
that have few if any clinical therapeutic options. ViroPharma is developing a
portfolio of therapeutics for rare and Orphan diseases including C1 esterase
inhibitor deficiency, Friedreich's Ataxia, and adrenal insufficiency; and
recurrent C. difficile infection (CDI). Our goal is to provide rewarding
careers to employees, to create new standards of care in the way serious
diseases are treated, and to build international partnerships with the
patients, advocates, and health care professionals we serve. ViroPharma's
commercial products address diseases including hereditary angioedema (HAE),
seizures and C. difficile-associated diarrhea (CDAD); for full U.S.
prescribing information on our products, please download the package inserts
at; the prescribing information for
other countries can be found at

ViroPharma routinely posts information, including press releases, which may be
important to investors in the investor relations and media sections of our
company's web site, The company encourages investors to
consult these sections for more information on ViroPharma and our business.

SOURCE ViroPharma Incorporated

Contact: Robert A. Doody Jr., Assistant Director, Investor Relations,
ViroPharma Incorporated, +1-610-321-6290
Press spacebar to pause and continue. Press esc to stop.